Evidence map›Paper›PMID 41932752›Full record

ReviewImmunology and allergy clinics of North America2026

Emerging Therapies for Anaphylaxis.

Melanie C Dispenza

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immunology and allergy clinics of North America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Melanie C DispenzaDivision of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA. Electronic address: mdispen1@jhmi.edu.

Funding

Using BTK Inhibitors to Prevent Anaphylactic Drug ReactionsK23AI143965 · NIAID · JOHNS HOPKINS UNIVERSITY · PI DISPENZA, MELANIE C. · 2020 to 2024
$1.1M
Extracellular Vesicles as Biomarkers of Immediate Hypersensitivity ReactionsR21AI182531 · NIAID · JOHNS HOPKINS UNIVERSITY · PI DISPENZA, MELANIE C. · 2024 to 2025
$450k
NIAID NIH HHS K23 AI143965NIAID NIH HHS R21 AI182531
6 · The paper itself

Abstract

Anaphylaxis can be caused by several different mechanisms. Novel therapies on the horizon target these numerous pathways, including tyrosine kinase inhibitors, recombinant allergen-specific blocking antibodies, and monoclonals targeting KIT or inhibitory receptors. This article discusses potential new therapies for both the prevention and treatment of anaphylaxis that are currently in clinical development.

Indexed as

AnaphylaxisAllergensAnimalsAnti-Allergic AgentsAntibodies, MonoclonalDesensitization, ImmunologicHumansImmunoglobulin EProtein Kinase InhibitorsProto-Oncogene Proteins c-kitAllergensAnti-Allergic AgentsAntibodies, MonoclonalImmunoglobulin EProtein Kinase InhibitorsProto-Oncogene Proteins c-kitAnaphylaxisBruton tyrosine kinaseChronic urticariaFood allergyIgEKinaseKIT

Identifiers

PMID41932752
PMCPMC13539930

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.